ID   AAKG2_HUMAN             Reviewed;         569 AA.
AC   Q9UGJ0; Q53Y07; Q6NUI0; Q75MP4; Q9NUZ9; Q9UDN8; Q9ULX8;
DT   01-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   07-APR-2021, entry version 184.
DE   RecName: Full=5'-AMP-activated protein kinase subunit gamma-2;
DE            Short=AMPK gamma2;
DE            Short=AMPK subunit gamma-2;
DE   AltName: Full=H91620p;
GN   Name=PRKAG2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RA   Hattori A., Seki N., Hayashi A., Kozuma S., Muramatsu M., Saito T.;
RT   "Human homolog of AMPK gamma-1 chain.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=10698692; DOI=10.1042/bj3460659;
RA   Cheung P.C.F., Salt I.P., Davies S.P., Hardie D.G., Carling D.;
RT   "Characterization of AMP-activated protein kinase gamma-subunit isoforms
RT   and their role in AMP binding.";
RL   Biochem. J. 346:659-669(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RX   PubMed=11112354; DOI=10.1006/geno.2000.6376;
RA   Lang T.M., Yu L., Qiang T., Jiang J.M., Chen Z., Xin Y.R., Liu G.Y.,
RA   Zhao S.;
RT   "Molecular cloning, genomic organization, and mapping of PRKAG2, a heart
RT   abundant gamma-2 subunit of 5'-AMP-activated protein kinase, to human
RT   chromosome 7q36.";
RL   Genomics 70:258-263(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS B AND C).
RC   TISSUE=Brain, and Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   DOMAIN CBS, AMP-BINDING, ATP-BINDING, CHARACTERIZATION OF VARIANTS WPWS
RP   GLN-302; ARG-383 AND ASN-400, CHARACTERIZATION OF VARIANT WPWS GLY-531, AND
RP   FUNCTION.
RX   PubMed=14722619; DOI=10.1172/jci200419874;
RA   Scott J.W., Hawley S.A., Green K.A., Anis M., Stewart G., Scullion G.A.,
RA   Norman D.G., Hardie D.G.;
RT   "CBS domains form energy-sensing modules whose binding of adenosine ligands
RT   is disrupted by disease mutations.";
RL   J. Clin. Invest. 113:274-284(2004).
RN   [9]
RP   DOMAIN AMPK PSEUDOSUBSTRATE, AND MUTAGENESIS OF VAL-387.
RX   PubMed=17255938; DOI=10.1038/sj.emboj.7601542;
RA   Scott J.W., Ross F.A., Liu J.K., Hardie D.G.;
RT   "Regulation of AMP-activated protein kinase by a pseudosubstrate sequence
RT   on the gamma subunit.";
RL   EMBO J. 26:806-815(2007).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   PHOSPHORYLATION BY ULK1.
RX   PubMed=21460634; DOI=10.4161/auto.7.7.15451;
RA   Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M.,
RA   Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.;
RT   "Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory
RT   feedback loop.";
RL   Autophagy 7:696-706(2011).
RN   [14]
RP   REVIEW ON FUNCTION.
RX   PubMed=17307971; DOI=10.1161/01.res.0000256090.42690.05;
RA   Towler M.C., Hardie D.G.;
RT   "AMP-activated protein kinase in metabolic control and insulin signaling.";
RL   Circ. Res. 100:328-341(2007).
RN   [15]
RP   REVIEW ON FUNCTION.
RX   PubMed=17712357; DOI=10.1038/nrm2249;
RA   Hardie D.G.;
RT   "AMP-activated/SNF1 protein kinases: conserved guardians of cellular
RT   energy.";
RL   Nat. Rev. Mol. Cell Biol. 8:774-785(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-71, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   VARIANT WPWS GLY-531.
RX   PubMed=11748095; DOI=10.1161/hc5001.102111;
RA   Gollob M.H., Seger J.J., Gollob T.N., Tapscott T., Gonzales O.,
RA   Bachinski L., Roberts R.;
RT   "Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular
RT   preexcitation and conduction system disease with childhood onset and
RT   absence of cardiac hypertrophy.";
RL   Circulation 104:3030-3033(2001).
RN   [18]
RP   VARIANTS CMH6 LEU-350 INS AND ARG-383.
RX   PubMed=11371514; DOI=10.1093/hmg/10.11.1215;
RA   Blair E., Redwood C., Ashrafian H., Oliveira M., Broxholme J., Kerr B.,
RA   Salmon A., Oestman-Smith I., Watkins H.;
RT   "Mutations in the gamma(2) subunit of AMP-activated protein kinase cause
RT   familial hypertrophic cardiomyopathy: evidence for the central role of
RT   energy compromise in disease pathogenesis.";
RL   Hum. Mol. Genet. 10:1215-1220(2001).
RN   [19]
RP   VARIANT WPWS GLN-302.
RX   PubMed=11407343; DOI=10.1056/nejm200106143442403;
RA   Gollob M.H., Green M.S., Tang A.S.-L., Gollob T., Karibe A.,
RA   Al Sayegh A.H., Ahmad F., Lozado R., Shah G., Fananapazir L.,
RA   Bachinski L.L., Roberts R.;
RT   "Identification of a gene responsible for familial Wolff-Parkinson-White
RT   syndrome.";
RL   N. Engl. J. Med. 344:1823-1831(2001).
RN   [20]
RP   ERRATUM OF PUBMED:11407343.
RA   Gollob M.H., Green M.S., Tang A.S.-L., Gollob T., Karibe A.,
RA   Al Sayegh A.H., Ahmad F., Lozado R., Shah G., Fananapazir L.,
RA   Bachinski L.L., Roberts R.;
RL   N. Engl. J. Med. 345:552-552(2001).
RN   [21]
RP   ERRATUM OF PUBMED:11407343.
RA   Gollob M.H., Green M.S., Tang A.S.-L., Gollob T., Karibe A.,
RA   Al Sayegh A.H., Ahmad F., Lozado R., Shah G., Fananapazir L.,
RA   Bachinski L.L., Roberts R.;
RL   N. Engl. J. Med. 346:300-300(2002).
RN   [22]
RP   VARIANTS CMH6 GLN-302; ASN-400 AND ILE-488.
RX   PubMed=11827995; DOI=10.1172/jci14571;
RA   Arad M., Benson D.W., Perez-Atayde A.R., McKenna W.J., Sparks E.A.,
RA   Kanter R.J., McGarry K., Seidman J.G., Seidman C.E.;
RT   "Constitutively active AMP kinase mutations cause glycogen storage disease
RT   mimicking hypertrophic cardiomyopathy.";
RL   J. Clin. Invest. 109:357-362(2002).
RN   [23]
RP   VARIANT GSDH GLN-531, AND CHARACTERIZATION OF VARIANT GSDH GLN-531.
RX   PubMed=15877279; DOI=10.1086/430840;
RA   Burwinkel B., Scott J.W., Buehrer C., van Landeghem F.K.H., Cox G.F.,
RA   Wilson C.J., Grahame Hardie D., Kilimann M.W.;
RT   "Fatal congenital heart glycogenosis caused by a recurrent activating R531Q
RT   mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2),
RT   not by phosphorylase kinase deficiency.";
RL   Am. J. Hum. Genet. 76:1034-1049(2005).
CC   -!- FUNCTION: AMP/ATP-binding subunit of AMP-activated protein kinase
CC       (AMPK), an energy sensor protein kinase that plays a key role in
CC       regulating cellular energy metabolism. In response to reduction of
CC       intracellular ATP levels, AMPK activates energy-producing pathways and
CC       inhibits energy-consuming processes: inhibits protein, carbohydrate and
CC       lipid biosynthesis, as well as cell growth and proliferation. AMPK acts
CC       via direct phosphorylation of metabolic enzymes, and by longer-term
CC       effects via phosphorylation of transcription regulators. Also acts as a
CC       regulator of cellular polarity by remodeling the actin cytoskeleton;
CC       probably by indirectly activating myosin. Gamma non-catalytic subunit
CC       mediates binding to AMP, ADP and ATP, leading to activate or inhibit
CC       AMPK: AMP-binding results in allosteric activation of alpha catalytic
CC       subunit (PRKAA1 or PRKAA2) both by inducing phosphorylation and
CC       preventing dephosphorylation of catalytic subunits. ADP also stimulates
CC       phosphorylation, without stimulating already phosphorylated catalytic
CC       subunit. ATP promotes dephosphorylation of catalytic subunit, rendering
CC       the AMPK enzyme inactive. {ECO:0000269|PubMed:14722619}.
CC   -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit (PRKAA1
CC       or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-catalytic
CC       subunits (PRKAG1, PRKAG2 or PRKAG3). Interacts with FNIP1 and FNIP2.
CC   -!- INTERACTION:
CC       Q9UGJ0; Q8NE08: COL25A1; NbExp=3; IntAct=EBI-2959705, EBI-25836642;
CC       Q9UGJ0; I6L9F6: NEFL; NbExp=3; IntAct=EBI-2959705, EBI-10178578;
CC       Q9UGJ0; Q13501: SQSTM1; NbExp=3; IntAct=EBI-2959705, EBI-307104;
CC       Q9UGJ0-3; P05067: APP; NbExp=3; IntAct=EBI-25939641, EBI-77613;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=A;
CC         IsoId=Q9UGJ0-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=Q9UGJ0-2; Sequence=VSP_000261;
CC       Name=C;
CC         IsoId=Q9UGJ0-3; Sequence=VSP_015589;
CC   -!- TISSUE SPECIFICITY: Isoform B is ubiquitously expressed except in liver
CC       and thymus. The highest level is detected in heart with abundant
CC       expression in placenta and testis.
CC   -!- DOMAIN: The AMPK pseudosubstrate motif resembles the sequence around
CC       sites phosphorylated on target proteins of AMPK, except the presence of
CC       a non-phosphorylatable residue in place of Ser. In the absence of AMP
CC       this pseudosubstrate sequence may bind to the active site groove on the
CC       alpha subunit (PRKAA1 or PRKAA2), preventing phosphorylation by the
CC       upstream activating kinase STK11/LKB1.
CC   -!- DOMAIN: The 4 CBS domains mediate binding to nucleotides. Of the 4
CC       potential nucleotide-binding sites, 3 are occupied, designated as sites
CC       1, 3, and 4 based on the CBS modules that provide the acidic residue
CC       for coordination with the 2'- and 3'-hydroxyl groups of the ribose of
CC       AMP. Of these, site 4 appears to be a structural site that retains a
CC       tightly held AMP molecule (AMP 3). The 2 remaining sites, 1 and 3, can
CC       bind either AMP, ADP or ATP. Site 1 (AMP, ADP or ATP 1) is the high-
CC       affinity binding site and likely accommodates AMP or ADP. Site 3 (AMP,
CC       ADP or ATP 2) is the weakest nucleotide-binding site on the gamma
CC       subunit, yet it is exquisitely sensitive to changes in nucleotide
CC       levels and this allows AMPK to respond rapidly to changes in cellular
CC       energy status. Site 3 is likely to be responsible for protection of a
CC       conserved threonine in the activation loop of the alpha catalytic
CC       subunit through conformational changes induced by binding of AMP or
CC       ADP. {ECO:0000250|UniProtKB:P80385}.
CC   -!- PTM: Phosphorylated by ULK1; leading to negatively regulate AMPK
CC       activity and suggesting the existence of a regulatory feedback loop
CC       between ULK1 and AMPK. {ECO:0000269|PubMed:21460634}.
CC   -!- DISEASE: Wolff-Parkinson-White syndrome (WPWS) [MIM:194200]: A
CC       supernormal conduction disorder characterized by the presence of one or
CC       several accessory atrioventricular connections, which can lead to
CC       episodes of sporadic tachycardia. {ECO:0000269|PubMed:11407343,
CC       ECO:0000269|PubMed:11748095, ECO:0000269|PubMed:14722619}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Cardiomyopathy, familial hypertrophic 6 (CMH6) [MIM:600858]: A
CC       hereditary heart disorder characterized by ventricular hypertrophy,
CC       which is usually asymmetric and often involves the interventricular
CC       septum. The symptoms include dyspnea, syncope, collapse, palpitations,
CC       and chest pain. They can be readily provoked by exercise. The disorder
CC       has inter- and intrafamilial variability ranging from benign to
CC       malignant forms with high risk of cardiac failure and sudden cardiac
CC       death. CMH6 patients present Wolff-Parkinson-White ventricular
CC       preexcitation, enlarged myocytes without myofiber disarray, and
CC       glycogen-containing cytosolic vacuoles within cardiomyocytes.
CC       {ECO:0000269|PubMed:11371514, ECO:0000269|PubMed:11827995}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Glycogen storage disease of heart lethal congenital (GSDH)
CC       [MIM:261740]: Rare disease which leads to death within a few weeks to a
CC       few months after birth, through heart failure and respiratory
CC       compromise. {ECO:0000269|PubMed:15877279}. Note=The disease is caused
CC       by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the 5'-AMP-activated protein kinase gamma
CC       subunit family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH20540.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAS02032.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAA84695.1; Type=Frameshift; Note=Frameshifts are upstream of the initiating Met of isoform B.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB025580; BAA84695.1; ALT_FRAME; mRNA.
DR   EMBL; AJ249976; CAB65116.1; -; mRNA.
DR   EMBL; AF087875; AAK00413.1; -; mRNA.
DR   EMBL; AK001887; BAA91962.1; -; mRNA.
DR   EMBL; BT007127; AAP35791.1; -; mRNA.
DR   EMBL; AC006358; AAS02032.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC006966; AAF03528.2; -; Genomic_DNA.
DR   EMBL; AC093583; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC020540; AAH20540.2; ALT_INIT; mRNA.
DR   EMBL; BC068598; AAH68598.1; -; mRNA.
DR   CCDS; CCDS43683.1; -. [Q9UGJ0-3]
DR   CCDS; CCDS47752.1; -. [Q9UGJ0-2]
DR   CCDS; CCDS5928.1; -. [Q9UGJ0-1]
DR   RefSeq; NP_001035723.1; NM_001040633.1. [Q9UGJ0-3]
DR   RefSeq; NP_001291456.1; NM_001304527.1.
DR   RefSeq; NP_001291460.1; NM_001304531.1. [Q9UGJ0-2]
DR   RefSeq; NP_057287.2; NM_016203.3. [Q9UGJ0-1]
DR   RefSeq; NP_077747.1; NM_024429.1. [Q9UGJ0-2]
DR   RefSeq; XP_016867759.1; XM_017012270.1. [Q9UGJ0-3]
DR   SMR; Q9UGJ0; -.
DR   BioGRID; 119531; 44.
DR   ComplexPortal; CPX-5786; AMPK complex, alpha1-beta1-gamma2 variant.
DR   ComplexPortal; CPX-5844; AMPK complex, alpha2-beta1-gamma2 variant.
DR   ComplexPortal; CPX-5845; AMPK complex, alpha2-beta2-gamma2 variant.
DR   ComplexPortal; CPX-5846; AMPK complex, alpha1-beta2-gamma2 variant.
DR   IntAct; Q9UGJ0; 28.
DR   STRING; 9606.ENSP00000287878; -.
DR   BindingDB; Q9UGJ0; -.
DR   ChEMBL; CHEMBL2453; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB00131; Adenosine phosphate.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB00273; Topiramate.
DR   iPTMnet; Q9UGJ0; -.
DR   PhosphoSitePlus; Q9UGJ0; -.
DR   BioMuta; PRKAG2; -.
DR   DMDM; 14285344; -.
DR   EPD; Q9UGJ0; -.
DR   jPOST; Q9UGJ0; -.
DR   MassIVE; Q9UGJ0; -.
DR   PaxDb; Q9UGJ0; -.
DR   PeptideAtlas; Q9UGJ0; -.
DR   PRIDE; Q9UGJ0; -.
DR   ProteomicsDB; 84222; -. [Q9UGJ0-1]
DR   ProteomicsDB; 84223; -. [Q9UGJ0-2]
DR   ProteomicsDB; 84224; -. [Q9UGJ0-3]
DR   Antibodypedia; 1327; 158 antibodies.
DR   DNASU; 51422; -.
DR   Ensembl; ENST00000287878; ENSP00000287878; ENSG00000106617. [Q9UGJ0-1]
DR   Ensembl; ENST00000392801; ENSP00000376549; ENSG00000106617. [Q9UGJ0-3]
DR   Ensembl; ENST00000418337; ENSP00000387386; ENSG00000106617. [Q9UGJ0-2]
DR   Ensembl; ENST00000476632; ENSP00000419493; ENSG00000106617. [Q9UGJ0-2]
DR   Ensembl; ENST00000651378; ENSP00000499103; ENSG00000106617. [Q9UGJ0-2]
DR   Ensembl; ENST00000651764; ENSP00000498796; ENSG00000106617. [Q9UGJ0-3]
DR   Ensembl; ENST00000652159; ENSP00000499025; ENSG00000106617. [Q9UGJ0-3]
DR   GeneID; 51422; -.
DR   KEGG; hsa:51422; -.
DR   UCSC; uc003wki.4; human. [Q9UGJ0-1]
DR   CTD; 51422; -.
DR   DisGeNET; 51422; -.
DR   GeneCards; PRKAG2; -.
DR   GeneReviews; PRKAG2; -.
DR   HGNC; HGNC:9386; PRKAG2.
DR   HPA; ENSG00000106617; Tissue enhanced (heart).
DR   MalaCards; PRKAG2; -.
DR   MIM; 194200; phenotype.
DR   MIM; 261740; phenotype.
DR   MIM; 600858; phenotype.
DR   MIM; 602743; gene.
DR   neXtProt; NX_Q9UGJ0; -.
DR   OpenTargets; ENSG00000106617; -.
DR   Orphanet; 439854; Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease.
DR   Orphanet; 155; NON RARE IN EUROPE: Familial isolated hypertrophic cardiomyopathy.
DR   Orphanet; 907; NON RARE IN EUROPE: Wolff-Parkinson-White syndrome.
DR   PharmGKB; PA33752; -.
DR   VEuPathDB; HostDB:ENSG00000106617.13; -.
DR   eggNOG; KOG1764; Eukaryota.
DR   GeneTree; ENSGT00950000183019; -.
DR   HOGENOM; CLU_021740_3_0_1; -.
DR   OMA; YYCQFPD; -.
DR   OrthoDB; 631088at2759; -.
DR   PhylomeDB; Q9UGJ0; -.
DR   TreeFam; TF313247; -.
DR   PathwayCommons; Q9UGJ0; -.
DR   Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane.
DR   Reactome; R-HSA-1632852; Macroautophagy.
DR   Reactome; R-HSA-163680; AMPK inhibits chREBP transcriptional activation activity.
DR   Reactome; R-HSA-200425; Carnitine metabolism.
DR   Reactome; R-HSA-2151209; Activation of PPARGC1A (PGC-1alpha) by phosphorylation.
DR   Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-9613354; Lipophagy.
DR   Reactome; R-HSA-9619483; Activation of AMPK downstream of NMDARs.
DR   SignaLink; Q9UGJ0; -.
DR   SIGNOR; Q9UGJ0; -.
DR   BioGRID-ORCS; 51422; 10 hits in 996 CRISPR screens.
DR   ChiTaRS; PRKAG2; human.
DR   GeneWiki; PRKAG2; -.
DR   GenomeRNAi; 51422; -.
DR   Pharos; Q9UGJ0; Tbio.
DR   PRO; PR:Q9UGJ0; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q9UGJ0; protein.
DR   Bgee; ENSG00000106617; Expressed in right atrium auricular region and 219 other tissues.
DR   ExpressionAtlas; Q9UGJ0; baseline and differential.
DR   Genevisible; Q9UGJ0; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0031588; C:nucleotide-activated protein kinase complex; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0043531; F:ADP binding; IDA:BHF-UCL.
DR   GO; GO:0016208; F:AMP binding; IBA:GO_Central.
DR   GO; GO:0004679; F:AMP-activated protein kinase activity; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IDA:BHF-UCL.
DR   GO; GO:0004862; F:cAMP-dependent protein kinase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0008603; F:cAMP-dependent protein kinase regulator activity; IMP:BHF-UCL.
DR   GO; GO:0008607; F:phosphorylase kinase regulator activity; IMP:BHF-UCL.
DR   GO; GO:0030295; F:protein kinase activator activity; IMP:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IDA:BHF-UCL.
DR   GO; GO:0019887; F:protein kinase regulator activity; IBA:GO_Central.
DR   GO; GO:0006754; P:ATP biosynthetic process; TAS:BHF-UCL.
DR   GO; GO:0006853; P:carnitine shuttle; TAS:Reactome.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:Reactome.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IBA:GO_Central.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0005977; P:glycogen metabolic process; IMP:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IMP:BHF-UCL.
DR   GO; GO:0016236; P:macroautophagy; TAS:Reactome.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0050790; P:regulation of catalytic activity; IBA:GO_Central.
DR   GO; GO:0042304; P:regulation of fatty acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0019217; P:regulation of fatty acid metabolic process; IMP:BHF-UCL.
DR   GO; GO:0046320; P:regulation of fatty acid oxidation; TAS:BHF-UCL.
DR   GO; GO:0046324; P:regulation of glucose import; TAS:BHF-UCL.
DR   GO; GO:0006110; P:regulation of glycolytic process; IMP:BHF-UCL.
DR   GO; GO:0016241; P:regulation of macroautophagy; TAS:Reactome.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0016126; P:sterol biosynthetic process; TAS:BHF-UCL.
DR   InterPro; IPR039170; AMPKG-2.
DR   InterPro; IPR000644; CBS_dom.
DR   PANTHER; PTHR13780:SF122; PTHR13780:SF122; 1.
DR   Pfam; PF00571; CBS; 3.
DR   SMART; SM00116; CBS; 4.
DR   PROSITE; PS51371; CBS; 4.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cardiomyopathy; CBS domain;
KW   Disease variant; Fatty acid biosynthesis; Fatty acid metabolism;
KW   Glycogen storage disease; Lipid biosynthesis; Lipid metabolism;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome; Repeat.
FT   CHAIN           1..569
FT                   /note="5'-AMP-activated protein kinase subunit gamma-2"
FT                   /id="PRO_0000204381"
FT   DOMAIN          275..335
FT                   /note="CBS 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00703"
FT   DOMAIN          357..415
FT                   /note="CBS 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00703"
FT   DOMAIN          430..492
FT                   /note="CBS 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00703"
FT   DOMAIN          504..562
FT                   /note="CBS 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00703"
FT   NP_BIND         319..322
FT                   /note="AMP, ADP or ATP 1"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   NP_BIND         383..384
FT                   /note="AMP, ADP or ATP 1"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   NP_BIND         458..459
FT                   /note="AMP 3"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   NP_BIND         474..477
FT                   /note="AMP, ADP or ATP 2"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   NP_BIND         530..531
FT                   /note="AMP, ADP or ATP 2"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   NP_BIND         546..549
FT                   /note="AMP 3"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   MOTIF           370..391
FT                   /note="AMPK pseudosubstrate"
FT   BINDING         302
FT                   /note="AMP, ADP or ATP 2"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   BINDING         362
FT                   /note="AMP, ADP or ATP 1; via amide nitrogen and carbonyl
FT                   oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   BINDING         383
FT                   /note="AMP 3"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   BINDING         402
FT                   /note="AMP, ADP or ATP 2"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   BINDING         432
FT                   /note="AMP 3"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   BINDING         437
FT                   /note="AMP 3; via amide nitrogen and carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   BINDING         501
FT                   /note="AMP, ADP or ATP 2"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   BINDING         509
FT                   /note="AMP, ADP or ATP 2; via amide nitrogen and carbonyl
FT                   oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   BINDING         530
FT                   /note="AMP 3"
FT                   /evidence="ECO:0000250|UniProtKB:P80385"
FT   MOD_RES         65
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91WG5"
FT   MOD_RES         71
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         73
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91WG5"
FT   MOD_RES         90
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91WG5"
FT   MOD_RES         138
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91WG5"
FT   MOD_RES         143
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91WG5"
FT   MOD_RES         161
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91WG5"
FT   MOD_RES         162
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91WG5"
FT   MOD_RES         165
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91WG5"
FT   MOD_RES         196
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91WG5"
FT   VAR_SEQ         1..241
FT                   /note="Missing (in isoform B)"
FT                   /evidence="ECO:0000303|PubMed:11112354,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|Ref.1, ECO:0000303|Ref.5"
FT                   /id="VSP_000261"
FT   VAR_SEQ         1..44
FT                   /note="Missing (in isoform C)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_015589"
FT   VARIANT         6
FT                   /note="M -> L (in dbSNP:rs3207363)"
FT                   /id="VAR_048250"
FT   VARIANT         302
FT                   /note="R -> Q (in WPWS and CMH6; impaired AMP- and ATP-
FT                   binding; dbSNP:rs121908987)"
FT                   /evidence="ECO:0000269|PubMed:11407343,
FT                   ECO:0000269|PubMed:11827995, ECO:0000269|PubMed:14722619"
FT                   /id="VAR_013264"
FT   VARIANT         350
FT                   /note="R -> RL (in CMH6; severe)"
FT                   /evidence="ECO:0000269|PubMed:11371514"
FT                   /id="VAR_013265"
FT   VARIANT         383
FT                   /note="H -> R (in CMH6; severe; impaired AMP- and ATP-
FT                   binding; dbSNP:rs121908988)"
FT                   /evidence="ECO:0000269|PubMed:11371514,
FT                   ECO:0000269|PubMed:14722619"
FT                   /id="VAR_013266"
FT   VARIANT         400
FT                   /note="T -> N (in CMH6; severe; impaired AMP- and ATP-
FT                   binding; dbSNP:rs28938173)"
FT                   /evidence="ECO:0000269|PubMed:11827995,
FT                   ECO:0000269|PubMed:14722619"
FT                   /id="VAR_013267"
FT   VARIANT         488
FT                   /note="N -> I (in CMH6; severe; dbSNP:rs121908989)"
FT                   /evidence="ECO:0000269|PubMed:11827995"
FT                   /id="VAR_013268"
FT   VARIANT         531
FT                   /note="R -> G (in WPWS; absence of cardiac hypertrophy;
FT                   onset in childhood; impaired AMP- and ATP-binding;
FT                   dbSNP:rs121908990)"
FT                   /evidence="ECO:0000269|PubMed:11748095,
FT                   ECO:0000269|PubMed:14722619"
FT                   /id="VAR_032909"
FT   VARIANT         531
FT                   /note="R -> Q (in GSDH; reduction of binding affinities for
FT                   AMP and ATP; loss of cooperative binding; enhanced basal
FT                   activity; increased phosphorylation of the alpha-subunit;
FT                   dbSNP:rs121908991)"
FT                   /evidence="ECO:0000269|PubMed:15877279"
FT                   /id="VAR_013269"
FT   MUTAGEN         387
FT                   /note="V->S: Induces phosphorylation by AMPK."
FT                   /evidence="ECO:0000269|PubMed:17255938"
SQ   SEQUENCE   569 AA;  63066 MW;  F51C30668C294089 CRC64;
     MGSAVMDTKK KKDVSSPGGS GGKKNASQKR RSLRVHIPDL SSFAMPLLDG DLEGSGKHSS
     RKVDSPFGPG SPSKGFFSRG PQPRPSSPMS APVRPKTSPG SPKTVFPFSY QESPPRSPRR
     MSFSGIFRSS SKESSPNSNP ATSPGGIRFF SRSRKTSGLS SSPSTPTQVT KQHTFPLESY
     KHEPERLENR IYASSSPPDT GQRFCPSSFQ SPTRPPLASP THYAPSKAAA LAAALGPAEA
     GMLEKLEFED EAVEDSESGV YMRFMRSHKC YDIVPTSSKL VVFDTTLQVK KAFFALVANG
     VRAAPLWESK KQSFVGMLTI TDFINILHRY YKSPMVQIYE LEEHKIETWR ELYLQETFKP
     LVNISPDASL FDAVYSLIKN KIHRLPVIDP ISGNALYILT HKRILKFLQL FMSDMPKPAF
     MKQNLDELGI GTYHNIAFIH PDTPIIKALN IFVERRISAL PVVDESGKVV DIYSKFDVIN
     LAAEKTYNNL DITVTQALQH RSQYFEGVVK CNKLEILETI VDRIVRAEVH RLVVVNEADS
     IVGIISLSDI LQALILTPAG AKQKETETE
//
